Skip to main content

Table 1 Studies with cytotoxic chemotherapy alone or in combination with biologic agents

From: Systemic therapy for recurrent or metastatic salivary gland malignancies

Author (year) Regimen No of patients Histology Progression required ORR CBR Median OS (months)
Airoldi et al. [6] Vino vs Cis + Vino 20 vs 16 Ad (9), ACC (22), MEC (1), others (4) Yes 20 % vs 44 % 65 % vs 81 % 8.5 vs 10
Gedlicka et al. [7] Mitoxantrone + Cis 14 NR No 14 % 79 % 27
Gilbert et al. [11] Paclitaxel 45 Ad (17), ACC (14), MEC (14) No 18 % 51 % 12.5
van Herpen et al.[12] Gemcitabine 21 ACC (21) No 0 % 52 % NR
Ross et al. [10] Epirubicin + Plat + 5FU 8 ACC (8) No 12 % 75 % 27
Laurie et al. [8] Plat + Gemcitabine 33 Ad (8), ACC (10), MEC (4), others (11) Yesa 24 % 82 % 13.8
Ghosal et al. [47] Cis + Imatinib 28 ACC (28) No 11 % 79 % 35
Argiris et al. [50] Bor → Bor + Dox 24 ACC (24) Yes 0 % and 8 %b 63 % and 58%b 21
Hitre et al. [49] Cetuximab + Cis + 5FU 12 ACC (12) No 42 % 92 % 24
Airoldi et al. [9] Cis + Vino 60 Ad (15), ACC (34) Yes 23 % 57 % 10c
  1. 5FU 5-florouracil, ACC adenoid cystic carcinoma; Ad adenocarcinoma, Bor bortezomib, Cis cisplatin, Dox Doxorubicin, MEC mucoepidermoid carcinoma, Plat platinum, Vino vinorelbine, NR not reported
  2. anot required for adenoid cystic carcinoma
  3. bresponse rates for Bor and Bor + Dox combination respectively
  4. cmedian survival for first-line patients only